mRNA |
GSK461364 |
CTRPv2 |
pan-cancer |
AAC |
0.029 |
0.4 |
mRNA |
BEC |
CTRPv2 |
pan-cancer |
AAC |
-0.066 |
0.4 |
mRNA |
Doxorubicin |
CTRPv2 |
pan-cancer |
AAC |
-0.027 |
0.4 |
mRNA |
brivanib |
CTRPv2 |
pan-cancer |
AAC |
0.032 |
0.4 |
mRNA |
ISOX |
CTRPv2 |
pan-cancer |
AAC |
-0.029 |
0.4 |
mRNA |
carboplatin:etoposide (40:17 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.027 |
0.4 |
mRNA |
cediranib |
CTRPv2 |
pan-cancer |
AAC |
-0.049 |
0.4 |
mRNA |
PI-103 |
CTRPv2 |
pan-cancer |
AAC |
-0.031 |
0.4 |
mRNA |
BRD-K03911514 |
CTRPv2 |
pan-cancer |
AAC |
-0.047 |
0.4 |
mRNA |
BRD-A02303741:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.032 |
0.4 |